Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Israeli Healthcare Professionals only

      Ubrelvy_dosing_banner
      • Taken orally, with or without food1
      • Take 50 mg or 100 mg to treat a migraine attack1
      • A second dose can be taken at least 2 hours after the initial dose, if needed1
      • The maximum dose in a 24-hour period is 200 mg1
      • Stored below 25°C1
      • Safety established in up to 8 migraines in a 30-day period1
      Ubrelvy_Pack

      Tablet not actual size

      ubrelvy_dosing

      Dosing considerations:

      • UBRELVY should not be used in case of history of hypersensitivity to the active substance or to any of the excipients
      • UBRELVY should not be used concomitantly with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, as they may cause an increase in UBRELVY exposure1
      • Strong CYP3A4 inducers should be avoided as concomitant use will result in reduction of ubrogepant exposure1
      • Patients on moderate or weak CYP3A4 inhibitors or inducers or BCRP and/or P-gp only inhibitors will require dose modifications1
      • Avoid use in patients with end-stage renal disease1
      • Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice. Avoid second dose within 24 hours1
      • Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose1
      • In clinical trials, patients were able to use concomitant preventive medications including topiramate, onabotulinumtoxinA, propranolol, and amitriptyline.3 None of these patients were on concomitant preventive medication that act on the CGRP pathway1
      ubrelvy_dosing_table

      For more information please contact us, and our team will answer your questions

      Contact Us

      References:

      1. Ubrelvy Israel Prescribing information, July 2022. 
      2. Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101. 
      3. Blumenfeld AM, Knievel K, Adams AM, et al. Ubrogepant is safe and efficacious in participants taking concomitant preventive medication for migraine: a pooled analysis of phase 3 trials. Adv Ther. Published online December 7, 2021.

      IL-UBR-220001 | September 2022